{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:47:14Z","timestamp":1791265634734,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jamda.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Medical Directors Association"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jamda.2015.08.007","type":"journal-article","created":{"date-parts":[[2015,9,27]],"date-time":"2015-09-27T01:02:57Z","timestamp":1443315777000},"page":"24-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"17","author":[{"given":"Kelvin K.F.","family":"Tsoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoyee W.","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce Y.C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.Y.","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jamda.2015.08.007_bib1","doi-asserted-by":"crossref","first-page":"f5125","DOI":"10.1136\/bmj.f5125","article-title":"Political drive to screen for pre-dementia: Not evidenced based and ignores the harms of diagnosis","volume":"347","author":"Le Couteur","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jamda.2015.08.007_bib2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-159-9-201311050-00730","article-title":"Screening for cognitive impairment in older adults: A systematic review for the U.S. Preventive Services Task Force","volume":"159","author":"Lin","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jamda.2015.08.007_bib3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1365-2389.2003.51306.x","article-title":"Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease","volume":"51","author":"Geldmacher","year":"2003","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jamda.2015.08.007_bib4","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","article-title":"Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomised controlled trials","volume":"6","author":"Kavirajan","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jamda.2015.08.007_bib5","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1161\/01.STR.0000020094.08790.49","article-title":"Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300)","volume":"33","author":"Orgogozo","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.jamda.2015.08.007_bib6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2165\/00002512-200118110-00006","article-title":"Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: Epidemiology and management","volume":"18","author":"Gauthier","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jamda.2015.08.007_bib7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/gps.2384","article-title":"A\u00a0review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors","volume":"25","author":"Jones","year":"2010","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jamda.2015.08.007_bib8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0278-5846(01)00326-8","article-title":"Long-term effects of rivastigmine in moderately severe Alzheimer's disease. Does early initiation of therapy offer sustained benefits?","volume":"26","author":"Doraiswamy","year":"2002","journal-title":"Prog Neuropsychoparmacol Biol Psychiatry"},{"key":"10.1016\/j.jamda.2015.08.007_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000008243","article-title":"A\u00a052-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease","volume":"44","author":"Farlow","year":"2000","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jamda.2015.08.007_bib10","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jamda.2015.08.007_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000074140","article-title":"Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine","volume":"17","author":"Bullock","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.jamda.2015.08.007_bib12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1468-1331.2003.00677.x","article-title":"Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease","volume":"10","author":"Kurz","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jamda.2015.08.007_bib13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2165\/00023210-200317120-00004","article-title":"Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease","volume":"17","author":"Small","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jamda.2015.08.007_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00019442-200409000-00005","article-title":"Long-term outcomes of galantamine treatment in patients with Alzheimer disease","volume":"12","author":"Lyketsos","year":"2004","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jamda.2015.08.007_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archneur.63.1.49","article-title":"A\u00a024-week open-label extension study of memantine in moderate to severe Alzheimer disease","volume":"63","author":"Reisberg","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jamda.2015.08.007_bib16","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1503\/cmaj.051432","article-title":"Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: A randomized controlled trial","volume":"174","author":"Rockwood","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.jamda.2015.08.007_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000203887","article-title":"Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: Result from a 52-week, open-label, multicenter, extension study in Japan","volume":"27","author":"Homma","year":"2009","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.jamda.2015.08.007_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00406-011-0234-2","article-title":"Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: A 12-month randomized, placebo-controlled, double-blinded study","volume":"262","author":"Likitjaroen","year":"2012","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.jamda.2015.08.007_bib19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000091790","article-title":"3-year study of donepezil therapy in Alzheimer's disease: Effects of early and continuous therapy","volume":"21","author":"Winblad","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.jamda.2015.08.007_bib20","first-page":"351","article-title":"Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease","volume":"254","author":"Ott","year":"2007","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.jamda.2015.08.007_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000017114","article-title":"Two-year treatment of Alzheimer's disease with eptastigmine","volume":"10","author":"Imbimbo","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.jamda.2015.08.007_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archneur.58.3.427","article-title":"Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease","volume":"58","author":"Doody","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jamda.2015.08.007_bib23","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1185\/030079904125004204","article-title":"Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: Results of a 52-week open-label study","volume":"20","author":"Aupperle","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jamda.2015.08.007_bib24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1468-1331.2004.00885.x","article-title":"Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: Multicenter trial","volume":"11","author":"Pirttila","year":"2004","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jamda.2015.08.007_bib25","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/gps.1746","article-title":"Efficacy and safety of donepezil over 3 years: An open-label, multicenter study in patients with Alzheimer's disease","volume":"22","author":"Burns","year":"2007","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jamda.2015.08.007_bib26","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.jamda.2015.08.007_bib27","series-title":"Diagnostic and statistical manual of mental disorders","year":"1994"},{"key":"10.1016\/j.jamda.2015.08.007_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state.\u201d A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.jamda.2015.08.007_bib29","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A\u00a0new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jamda.2015.08.007_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archneur.1994.00540130067012","article-title":"Severe impairment battery: A neuropsychological test for severely demented patients","volume":"51","author":"Panisset","year":"1994","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jamda.2015.08.007_bib31","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.jamda.2015.08.007_bib32","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.jamda.2015.08.007_bib33","first-page":"8","article-title":"Clinical global measures of dementia: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines","volume":"11","author":"Reisberg","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.jamda.2015.08.007_bib34","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jamda.2015.08.007_bib35","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jamda.2015.08.007_bib36","unstructured":"Review Manager (RevMan) (Computer program) version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration,\u00a02011."},{"key":"10.1016\/j.jamda.2015.08.007_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jamda.2015.08.007_bib38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jamda.2015.08.007_bib39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3233\/JAD-132690","article-title":"Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: A systematic review and meta-analysis","volume":"41","author":"Tan","year":"2014","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.jamda.2015.08.007_bib40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","article-title":"Donepezil for dementia in Parkinson's disease: A randomised, double blind, placebo controlled, crossover study","volume":"76","author":"Ravina","year":"2005","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jamda.2015.08.007_bib41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1258\/jrsm.96.7.320","article-title":"Dementia: Issues in early recognition and intervention in primary care","volume":"96","author":"Woods","year":"2003","journal-title":"J\u00a0R Soc Med"}],"container-title":["Journal of the American Medical Directors Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861015005332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861015005332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T20:39:37Z","timestamp":1748637577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525861015005332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1525861015005332"],"URL":"https:\/\/doi.org\/10.1016\/j.jamda.2015.08.007","relation":{},"ISSN":["1525-8610"],"issn-type":[{"value":"1525-8610","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Medical Directors Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jamda.2015.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 AMDA \u2013 The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}